2025 Q3 -tulosraportti
Vain PDF
26 päivää sitten
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
2
Myynti
Määrä
1 247
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 2 | - | - | ||
| 21 | - | - | ||
| 88 | - | - | ||
| 4 | - | - | ||
| 5 | - | - |
Ylin
45,35VWAP
Alin
43,25VaihtoMäärä
0,2 3 416
VWAP
Ylin
45,35Alin
43,25VaihtoMäärä
0,2 3 416
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 6.2.2026 |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 13.11. | |
| 2025 Q2 -tulosraportti | 20.8. | |
| 2025 Q1 -tulosraportti | 7.5. | |
| 2024 Q4 -tulosraportti | 13.2. | |
| 2024 Q3 -tulosraportti | 14.11.2024 |
Datan lähde: FactSet, Quartr
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·26.11.Ok - not very clever investors we're dealing with here. I'm surprised that after an FDA meeting they are pursuing the fast accelerated process instead of the longer standard BLA.!! 🤣
·26.11.Yes, but maybe they want to get the product out faster!? Now that they have a manufacturer in Recipharm!? Sometimes we don't have the full picture! My impression is that they have very good knowledge of both patents and studies, considering BioGaia! We'll see! Prematurely born children are being born and saved more and more nowadays….. important what they do!
·20.11.Another high-potential possibility is that we are acquired. Bio companies in niche areas rarely succeed alone due to a simple reason: they lack the competence to market the product, even though Infant B. "only" needs to enter absolute special hospitals, so a market-leading Pharma will presumably take over the marketing rights per region, USA. Europe. Asia will certainly be taken over by a Japanese company.- ·17.11.Massive drop since 1/9 without anything negative coming to light?!
·20.11.It is not as dramatic as it may sound. IBT has itself announced that they are in the process of securing production setup and scalability towards the planned BLA submission in 2026. But there are still open questions about when the final commercial production will be fully validated. This type of uncertainty is completely normal for small biotech companies, but the market typically reacts a bit overdramatically as long as there are no clear milestones or a fixed production partner. This does not change the fact that the data for IBP-9414 are strong, and FDA’s Breakthrough-status still stands. The short-term risk is primarily timing and execution, not the drug's effect itself. So, as I also wrote, it will be exciting to see if they realize it, as the substance is still a “one of a kind” substance.·23.11.IBT has delivered yet another strong week, where uncertainty about production is now replaced by concrete steps forward. The agreement with Recipharm provides a clear production partner and reduces one of the biggest risk factors before the BLA submission in 2026. It has almost all come as a response to my previous post. As said, it will be an exciting journey to follow IBT, but this agreement has brought us significantly closer to real commercialization. - ·9.9.What is the reason for Infant's recent upward race? I have a GAK of 120, and had actually ignored this stock because I thought everything was dead.·17.9. · MuokattuI think a submission and later approval is expected based on their latest trial (the one that failed in the primary endpoint, but showed a surprisingly lower mortality rate) I have a small 7-page ChatGPT dialogue lying around in my FB group "Dividend & Risk Stocks_Balanced Portfolio" - it was posted on 2/9'2025. NOTE: I myself have about 3,000 shares at GAK around 50 - bought up a lot after their big drop in connection with the "failed" trial in the expectation that the fact that fewer people died was probably something worth working on.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q3 -tulosraportti
Vain PDF
26 päivää sitten
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·26.11.Ok - not very clever investors we're dealing with here. I'm surprised that after an FDA meeting they are pursuing the fast accelerated process instead of the longer standard BLA.!! 🤣·26.11.Yes, but maybe they want to get the product out faster!? Now that they have a manufacturer in Recipharm!? Sometimes we don't have the full picture! My impression is that they have very good knowledge of both patents and studies, considering BioGaia! We'll see! Prematurely born children are being born and saved more and more nowadays….. important what they do!
- ·20.11.Another high-potential possibility is that we are acquired. Bio companies in niche areas rarely succeed alone due to a simple reason: they lack the competence to market the product, even though Infant B. "only" needs to enter absolute special hospitals, so a market-leading Pharma will presumably take over the marketing rights per region, USA. Europe. Asia will certainly be taken over by a Japanese company.
- ·17.11.Massive drop since 1/9 without anything negative coming to light?!·20.11.It is not as dramatic as it may sound. IBT has itself announced that they are in the process of securing production setup and scalability towards the planned BLA submission in 2026. But there are still open questions about when the final commercial production will be fully validated. This type of uncertainty is completely normal for small biotech companies, but the market typically reacts a bit overdramatically as long as there are no clear milestones or a fixed production partner. This does not change the fact that the data for IBP-9414 are strong, and FDA’s Breakthrough-status still stands. The short-term risk is primarily timing and execution, not the drug's effect itself. So, as I also wrote, it will be exciting to see if they realize it, as the substance is still a “one of a kind” substance.·23.11.IBT has delivered yet another strong week, where uncertainty about production is now replaced by concrete steps forward. The agreement with Recipharm provides a clear production partner and reduces one of the biggest risk factors before the BLA submission in 2026. It has almost all come as a response to my previous post. As said, it will be an exciting journey to follow IBT, but this agreement has brought us significantly closer to real commercialization.
- ·9.9.What is the reason for Infant's recent upward race? I have a GAK of 120, and had actually ignored this stock because I thought everything was dead.·17.9. · MuokattuI think a submission and later approval is expected based on their latest trial (the one that failed in the primary endpoint, but showed a surprisingly lower mortality rate) I have a small 7-page ChatGPT dialogue lying around in my FB group "Dividend & Risk Stocks_Balanced Portfolio" - it was posted on 2/9'2025. NOTE: I myself have about 3,000 shares at GAK around 50 - bought up a lot after their big drop in connection with the "failed" trial in the expectation that the fact that fewer people died was probably something worth working on.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
2
Myynti
Määrä
1 247
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 2 | - | - | ||
| 21 | - | - | ||
| 88 | - | - | ||
| 4 | - | - | ||
| 5 | - | - |
Ylin
45,35VWAP
Alin
43,25VaihtoMäärä
0,2 3 416
VWAP
Ylin
45,35Alin
43,25VaihtoMäärä
0,2 3 416
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 6.2.2026 |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 13.11. | |
| 2025 Q2 -tulosraportti | 20.8. | |
| 2025 Q1 -tulosraportti | 7.5. | |
| 2024 Q4 -tulosraportti | 13.2. | |
| 2024 Q3 -tulosraportti | 14.11.2024 |
Datan lähde: FactSet, Quartr
2025 Q3 -tulosraportti
Vain PDF
26 päivää sitten
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 6.2.2026 |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 13.11. | |
| 2025 Q2 -tulosraportti | 20.8. | |
| 2025 Q1 -tulosraportti | 7.5. | |
| 2024 Q4 -tulosraportti | 13.2. | |
| 2024 Q3 -tulosraportti | 14.11.2024 |
Datan lähde: FactSet, Quartr
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·26.11.Ok - not very clever investors we're dealing with here. I'm surprised that after an FDA meeting they are pursuing the fast accelerated process instead of the longer standard BLA.!! 🤣·26.11.Yes, but maybe they want to get the product out faster!? Now that they have a manufacturer in Recipharm!? Sometimes we don't have the full picture! My impression is that they have very good knowledge of both patents and studies, considering BioGaia! We'll see! Prematurely born children are being born and saved more and more nowadays….. important what they do!
- ·20.11.Another high-potential possibility is that we are acquired. Bio companies in niche areas rarely succeed alone due to a simple reason: they lack the competence to market the product, even though Infant B. "only" needs to enter absolute special hospitals, so a market-leading Pharma will presumably take over the marketing rights per region, USA. Europe. Asia will certainly be taken over by a Japanese company.
- ·17.11.Massive drop since 1/9 without anything negative coming to light?!·20.11.It is not as dramatic as it may sound. IBT has itself announced that they are in the process of securing production setup and scalability towards the planned BLA submission in 2026. But there are still open questions about when the final commercial production will be fully validated. This type of uncertainty is completely normal for small biotech companies, but the market typically reacts a bit overdramatically as long as there are no clear milestones or a fixed production partner. This does not change the fact that the data for IBP-9414 are strong, and FDA’s Breakthrough-status still stands. The short-term risk is primarily timing and execution, not the drug's effect itself. So, as I also wrote, it will be exciting to see if they realize it, as the substance is still a “one of a kind” substance.·23.11.IBT has delivered yet another strong week, where uncertainty about production is now replaced by concrete steps forward. The agreement with Recipharm provides a clear production partner and reduces one of the biggest risk factors before the BLA submission in 2026. It has almost all come as a response to my previous post. As said, it will be an exciting journey to follow IBT, but this agreement has brought us significantly closer to real commercialization.
- ·9.9.What is the reason for Infant's recent upward race? I have a GAK of 120, and had actually ignored this stock because I thought everything was dead.·17.9. · MuokattuI think a submission and later approval is expected based on their latest trial (the one that failed in the primary endpoint, but showed a surprisingly lower mortality rate) I have a small 7-page ChatGPT dialogue lying around in my FB group "Dividend & Risk Stocks_Balanced Portfolio" - it was posted on 2/9'2025. NOTE: I myself have about 3,000 shares at GAK around 50 - bought up a lot after their big drop in connection with the "failed" trial in the expectation that the fact that fewer people died was probably something worth working on.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
2
Myynti
Määrä
1 247
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 2 | - | - | ||
| 21 | - | - | ||
| 88 | - | - | ||
| 4 | - | - | ||
| 5 | - | - |
Ylin
45,35VWAP
Alin
43,25VaihtoMäärä
0,2 3 416
VWAP
Ylin
45,35Alin
43,25VaihtoMäärä
0,2 3 416
Välittäjätilasto
Dataa ei löytynyt